ஜூலியா டெஉட்ஸ்ச் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜூலியா டெஉட்ஸ்ச். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜூலியா டெஉட்ஸ்ச் Today - Breaking & Trending Today

Zentera Therapeutics Announces - GuruFocus.com

Zentera Therapeutics Announces - GuruFocus.com
gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.

New York , United States , San Diego , Hong Kong , San Francisco , Julia Deutsch , Anthony Sun , Gitanjali Jain , Exchange Commission , Redmile Group , Zentalis Pharmaceuticals Inc , Zentera Therapeutics Inc , Orbimed Advisors Asia , Tybourne Capital Management , Avidity Partners , Casdin Capital , Surveyor Capital , Farallon Capital Management , Lilly Asia Ventures , Logos Capital , Perceptive Advisors , Viking Global Investors , Zentalis Pharmaceuticals , Clinical Trial Applications , Chief Executive Officer , Capital Management ,

Zentera Therapeutics Announces Closing of $75 Million Series B Financing

Zentera Therapeutics Announces Closing of $75 Million Series B Financing
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

New York , United States , San Diego , Hong Kong , San Francisco , Julia Deutsch , Anthony Sun , Gitanjali Jain , Exchange Commission , Redmile Group , Zentalis Pharmaceuticals Inc , Zentera Therapeutics Inc , Orbimed Advisors Asia , Tybourne Capital Management , Avidity Partners , Casdin Capital , Surveyor Capital , Farallon Capital Management , Lilly Asia Ventures , Logos Capital , Perceptive Advisors , Viking Global Investors , Zentalis Pharmaceuticals , Clinical Trial Applications , Chief Executive Officer , Capital Management ,

Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock
ZENTALIS PHARMACEUTICALSJune 29, 2021 GMT
NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the pricing of an underwritten public offering of 3,100,000 shares of its common stock at a public offering price of $48.50 per share, for total gross proceeds of approximately $150.4 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the common stock is being offered by Zentalis. The offering is expected to close on July 1, 2021, subject to customary closing conditions. In addition, Zentalis has granted the underwriters a 3 ....

New York , United States , San Diego , Wedbush Pacgrow , Julia Deutsch , Gitanjali Jain Ogawa , Morgan Stanley , Equity Syndicate Department , Zentalis Pharmaceuticals Inc , Zentalis Pharmaceuticals , Guggenheim Securities , Exchange Commission , Prospectus Department , Equity Syndicate Prospectus Department , Syndicate Department , Morgan Stanley Co , Second Floor , One Federal Street , Zentera Therapeutics , Private Securities Litigation Reform Act , Quarterly Report , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , சான் டியாகோ , ஜூலியா டெஉட்ஸ்ச் , கீதன்ஜலி ஜெயின் ஓகாவா ,

Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock - Press Release

NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the pricing of an underwritten public offering of 3,100,000 shares of its common stock at a public offering price of $48.50 per share, for total gross proceeds of approximately $150.4 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the common stock is being offered by Zentalis. The offering is expected to close on July 1, 2021, subject to customary closing conditions. In addition, Zentalis has granted the underwriters a 30-day option to purchase up to an additional 465,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. ....

New York , United States , San Diego , Wedbush Pacgrow , Julia Deutsch , Gitanjali Jain Ogawa , Morgan Stanley , Equity Syndicate Department , Zentalis Pharmaceuticals Inc , Zentalis Pharmaceuticals , Guggenheim Securities , Exchange Commission , Prospectus Department , Equity Syndicate Prospectus Department , Syndicate Department , Morgan Stanley Co , Second Floor , One Federal Street , Zentera Therapeutics , Private Securities Litigation Reform Act , Quarterly Report , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , சான் டியாகோ , ஜூலியா டெஉட்ஸ்ச் , கீதன்ஜலி ஜெயின் ஓகாவா ,

Zentalis Pharmaceuticals Announces Pricing of Offering of

Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock
June 28, 2021 21:09 ET
| Source:
ZENTALIS PHARMACEUTICALS
ZENTALIS PHARMACEUTICALS
New York, New York, UNITED STATES
NEW YORK and SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the pricing of an underwritten public offering of 3,100,000 shares of its common stock at a public offering price of $48.50 per share, for total gross proceeds of approximately $150.4 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis. All of the common stock is being offered by Zentalis. The offering is expected to close on July 1, 2021, subject to customary closing conditions. In addition, ....

New York , United States , San Diego , Wedbush Pacgrow , Julia Deutsch , Gitanjali Jain Ogawa , Morgan Stanley , Equity Syndicate Department , Zentalis Pharmaceuticals Inc , Zentalis Pharmaceuticals , Guggenheim Securities , Exchange Commission , Prospectus Department , Equity Syndicate Prospectus Department , Syndicate Department , Morgan Stanley Co , Second Floor , One Federal Street , Zentera Therapeutics , Private Securities Litigation Reform Act , Quarterly Report , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , சான் டியாகோ , ஜூலியா டெஉட்ஸ்ச் , கீதன்ஜலி ஜெயின் ஓகாவா ,